This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of epilepsy: A Synthesis of Findings from 92 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of epilepsy: A Synthesis of Findings from 92 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Numerous studies have revealed significant insights into the treatment of epilepsy. 61 provides a comprehensive overview of treatment options for metabolic epilepsy, highlighting the need for therapies that address the underlying metabolic abnormalities, as conventional antiepileptic drugs often fail to do so. Targeting the root cause of metabolic disturbances can lead to improvements in behavior, cognitive function, and reduced seizure frequency or severity. 71 explores the use of vigabatrin as an add-on therapy for drug-resistant focal epilepsy, suggesting its potential effectiveness in managing this specific type of epilepsy. 17 examines the efficacy of surgery for intractable epilepsy through a meta-analysis, indicating that surgery can be a successful treatment option. Furthermore, 26 demonstrates the efficacy of clobazam as an add-on therapy for refractory epilepsy. 27 investigates the effectiveness of ethosuximide, valproic acid, and lamotrigine for treating childhood absence epilepsy, the most prevalent pediatric epilepsy syndrome, although the optimal first-line treatment remains undefined. 72 delves into the molecular mechanisms of epileptogenesis and explores novel therapeutic approaches. The study highlights the role of neuroinflammation, neurodegeneration, and epigenetic modifications in the development of epilepsy. 90 presents a phase 2b randomized clinical trial evaluating the efficacy and safety of XEN1101, a novel potassium channel opener, for treating adults with focal epilepsy. 53 compares the effectiveness of lamotrigine and carbamazepine for monotherapy in epilepsy through a meta-analysis of individual participant data, indicating lamotrigine's potential superiority. 82 investigates the characteristics of individuals with epilepsy in three Eastern African countries, highlighting the significant treatment gap, particularly in sub-Saharan Africa. 48 explores the use of melatonin as an add-on therapy for epilepsy, suggesting its potential as a safe antiepileptic medication. 89 systematically reviews and meta-analyzes the safety and efficacy of brivaracetam for treating childhood epilepsy, highlighting its effectiveness and safety in this population. 65 systematically reviews and meta-analyzes the quality of life of children after epilepsy surgery, indicating that surgery can improve their quality of life. 32 provides an updated Cochrane Review on the effectiveness of levetiracetam as an add-on therapy for drug-resistant focal epilepsy, suggesting its effectiveness in managing this challenging form of epilepsy. 57 conducts a network meta-analysis of individual participant data, comparing the effectiveness of various antiepileptic drug monotherapies for epilepsy. 81 provides an updated Cochrane Review on the effectiveness of felbamate as an add-on therapy for drug-resistant focal epilepsy, suggesting its potential effectiveness in this patient population. 79 systematically reviews and meta-analyzes the efficacy of lamotrigine in epilepsy patients who have failed initial valproate treatment, indicating lamotrigine's potential effectiveness in this context. 25 investigates the efficacy of rufinamide for generalized seizures associated with Lennox-Gastaut syndrome, suggesting its potential effectiveness for managing this complex and challenging pediatric epilepsy syndrome. 20 explores the potential of hippocampal electrical stimulation as a treatment for mesial temporal lobe epilepsy (MTLE). 29 compares the effectiveness of progesterone and placebo therapy for intractable seizures in women with partial epilepsy through a randomized clinical trial. 38 reports on a multicenter pilot treatment trial for psychogenic nonepileptic seizures, highlighting the need for more controlled treatment trials for this common conversion disorder. 4 compares the treatment outcomes of uncomplicated childhood epilepsy after one and three years of treatment, suggesting the prognostic value of EEG parameters for predicting remission rates after discontinuing antiepileptic drug therapy. 46 provides an updated Cochrane Review on the effectiveness of melatonin as an add-on therapy for epilepsy, suggesting its potential as a safe antiepileptic medication. 33 meta-analyzes the therapeutic effects of selective amygdalohippocampectomy and anterior temporal lobectomy for treating temporal lobe epilepsy. 84 systematically reviews the cost-effectiveness of surgical treatment compared to medical treatment for patients with drug-refractory epilepsy, suggesting that surgical treatment may be more cost-effective. 91 provides an updated Cochrane Review on immunomodulatory interventions for focal epilepsy, highlighting the potential of targeting inflammatory pathways as a novel therapeutic strategy. 21 investigates the impact of treating the first tonic-clonic seizure on long-term remission of epilepsy, suggesting that early treatment does not affect the long-term prognosis. 31 meta-analyzes the clinical efficacy and safety of newer antiepileptic drugs, such as eslicarbazepine, retigabine/ezogabine, carisbamate, lacosamide, brivaracetam, and perampanel, as adjunctive therapy for adults with refractory partial-onset seizures. 22 explores the use of corticosteroids, including ACTH, for treating childhood epilepsy other than epileptic spasms, highlighting their potential efficacy but emphasizing the associated significant adverse effects. 55 conducts a review of individual participant data comparing the effectiveness of topiramate and carbamazepine monotherapy for epilepsy, suggesting no significant difference in efficacy. 15 presents a clinical observation study on 930 children with epilepsy treated with anti-epilepsy capsules, indicating their potential effectiveness in treating various types of epilepsy. 51 investigates the use of polyunsaturated fatty acid supplementation for drug-resistant epilepsy, showing inconsistent results but suggesting potential benefits. 62 systematically reviews and meta-analyzes the overall outcomes of surgical versus medical treatment for drug-resistant epilepsy. 10 examines the effectiveness of oxcarbazepine as an add-on therapy for drug-resistant partial epilepsy. 85 investigates the impact of melatonin add-on therapy on seizure outcomes and sleep quality in adults with idiopathic generalized tonic-clonic seizures. 30 further explores the potential of melatonin as an add-on therapy for epilepsy, emphasizing its safety profile. 80 provides an updated Cochrane Review comparing the effectiveness of various antiepileptic drug monotherapies for epilepsy through a network meta-analysis of individual participant data. 23 examines the effectiveness of non-pharmacological interventions for epilepsy in individuals with intellectual disabilities, emphasizing the need for high-quality randomized controlled trials (RCTs) in this population. 45 systematically reviews the evidence for using neuroimaging for surgical treatment of temporal lobe epilepsy. 34 examines the effectiveness of zonisamide as an add-on therapy for drug-resistant partial epilepsy. 1 investigates the use of phenytoin as a single drug treatment for epilepsy, suggesting its potential efficacy for many patients.

Treatment summary

For metabolic epilepsy, treatment strategies often focus on addressing the underlying metabolic abnormalities, such as through dietary modifications and supplementation. 61 Traditional antiepileptic drugs may not effectively address the root cause of this type of epilepsy, making these alternative approaches crucial.

Treating drug-resistant focal epilepsy often involves add-on therapies such as vigabatrin, 71 felbamate, 81 zonisamide, 34 oxcarbazepine, 10 levetiracetam, 32 and surgical interventions can also be effective. 17

Treating childhood epilepsy often involves medications such as ethosuximide, valproic acid, and lamotrigine. 27 Brivaracetam has proven to be both effective and safe for treating childhood epilepsy. 89 Surgical interventions can also improve the quality of life for children with epilepsy. 65

Benefits and risks

Benefit summary

Treatment for epilepsy has shown to reduce seizure frequency and severity, leading to improved quality of life. 61 Specifically, targeting the underlying metabolic abnormalities in metabolic epilepsy can lead to improvements in behavior and cognitive function. 61 Surgical interventions for drug-resistant focal epilepsy have demonstrated the potential for significantly reducing seizure frequency. 17 Melatonin has shown potential as a safe antiepileptic medication. 48 Brivaracetam has proven to be both effective and safe for treating childhood epilepsy. 89

Risk summary

Epilepsy treatments carry the potential for side effects. Antiepileptic medications can cause drowsiness, dizziness, unsteadiness, nausea, and weight gain. 71 Surgical interventions may involve risks of infection, bleeding, and cognitive decline. 17 Corticosteroids can cause side effects such as osteoporosis, hyperglycemia, and weight gain. 22

Comparison between studies

Commonalities between studies

Multiple studies underscore that epilepsy is a treatable condition, and appropriate treatment can effectively reduce seizure frequency and severity. The research emphasizes the importance of individualizing treatment plans, considering the availability of a wide range of antiepileptic medications and surgical interventions.

Differences between studies

Studies may present varying conclusions regarding the effectiveness of specific treatments and their associated risks. For instance, the effectiveness of polyunsaturated fatty acid supplementation for drug-resistant epilepsy remains inconclusive. 51 In some cases, conflicting results may emerge from different studies, highlighting the complexity of epilepsy and the need for a nuanced approach. Therefore, considering multiple research findings and tailoring treatment to individual patients is crucial.

Consistency and contradictions in results

Some studies present differing conclusions regarding the effectiveness and safety of specific therapies. For example, the efficacy of polyunsaturated fatty acid supplementation for treating drug-resistant epilepsy exhibits variability across studies. 51 Inconsistent findings may arise from different research methodologies or patient populations. This underscores the importance of a comprehensive evaluation of multiple research outcomes to make informed decisions regarding treatment choices for individual patients.

Practical application considerations

Epilepsy management requires a personalized approach, prioritizing the selection of treatments that best suit each individual's condition. Regular consultations with a physician are essential to monitor treatment progress, potential side effects, and any changes in condition. Open communication with your healthcare provider is crucial for making informed decisions about your treatment plan.

Limitations of current research

Despite the advancements in epilepsy treatment research, gaps in our understanding remain. Further research is necessary, particularly in the development of novel therapies and the thorough evaluation of the efficacy and safety of existing treatments. The diversity of epilepsy symptoms and causes presents a challenge in discovering universally effective therapies.

Future research directions

Advancements in epilepsy treatment research require focusing on the following key aspects:

  • Development of novel therapies.
  • In-depth investigations into the effectiveness and safety of existing therapies.
  • Research focused on identifying personalized treatment strategies for individual patients.
  • Unraveling the underlying mechanisms of epileptogenesis.

Conclusion

Epilepsy is a treatable condition, with appropriate treatment often leading to reduced seizure frequency and severity, resulting in improved quality of life. However, finding universally effective therapies can be challenging due to the diversity of epilepsy types and causes. A comprehensive evaluation of multiple research findings is essential to make informed decisions about treatment choices for individual patients. It is crucial to collaborate with your healthcare provider to develop a personalized treatment plan that addresses your specific needs and monitor your progress closely.

List of treatments

Dietary modifications, dietary supplements, vigabatrin, felbamate, zonisamide, oxcarbazepine, levetiracetam, surgical interventions, ethosuximide, valproic acid, lamotrigine, brivaracetam, melatonin, corticosteroids, phenytoin, polyunsaturated fatty acids.


Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 92 papers
Positive Content
84
Neutral Content
3
Negative Content
5
Article Type
22
31
66
49
89

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : French


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Spanish


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: KotulskaKatarzyna, KwiatkowskiDavid J, CuratoloPaolo, WeschkeBernhard, RineyKate, JansenFloor, FeuchtMartha, KrsekPavel, NabboutRima, JansenAnna C, WojdanKonrad, SijkoKamil, Głowacka-WalasJagoda, BorkowskaJulita, SadowskiKrzysztof, Domańska-PakiełaDorota, MoaveroRomina, HertzbergChristoph, HulshofHanna, SchollTheresa, BenovaBarbora, AronicaEleonora, de RidderJessie, LagaeLieven, JóźwiakSergiusz,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.